Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Tilray Inc

Start price
Target price
Perf. (%)
€6.34
14.11.20
-
14.11.21
-1.09%
27.11.20

Significant cyclical dependencies
Higher risks for its business
Probably not worthwhile Investment
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€51.30
14.11.20
-
14.11.21
-1.75%
23.11.20

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
buy
Qualcomm Inc.

Start price
Target price
Perf. (%)
€123.48
14.11.20
€150.00
14.05.21
-14.32%
14.05.21

Enzon Pharmaceuticals

Start price
Target price
Perf. (%)
€0.10
14.11.20
-
14.11.21
120.00%
14.01.21

Risky Investment
Nicheplayer
Higher risks for its business
buy
Verisk Analytics A

Start price
Target price
Perf. (%)
€174.02
13.11.20
-
13.11.21
-9.85%
13.02.21

EBIT growth >5% per year expected
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Very low/no dividend yield expected
buy
International Business Machines Corp

Start price
Target price
Perf. (%)
€98.48
13.11.20
€118.00
13.11.21
5.71%
14.11.21

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued
buy
Procter & Gamble Co.

Start price
Target price
Perf. (%)
€120.88
13.11.20
-
-14.54%
01.03.21

buy
International Business Machines Corp

Start price
Target price
Perf. (%)
€98.00
13.11.20
-
13.11.21
26.48%
10.06.21

buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€50.60
13.11.20
€52.00
1.38%
14.11.20

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
buy
Apple Inc.

Start price
Target price
Perf. (%)
€101.48
13.11.20
€110.00
3.84%
16.12.20

positive Cash Flow expected
Standard Investments for future growth
Valuable balance sheet
Normal challenges to pay loans and raise capital
buy
T-Mobile US Inc.

Start price
Target price
Perf. (%)
€106.88
12.11.20
€110.00
4.79%
14.11.20

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Valuable balance sheet
ROE higher than 10% per year
Truist Financial Corp.

Start price
Target price
Perf. (%)
€41.60
11.11.20
-
11.11.21
5.29%
14.01.21

Very high dividend yield expected
Probably not worthwhile Investment
Business model of the past or high risk
buy
General Motors Corp

Start price
Target price
Perf. (%)
€35.30
11.11.20
-
9.92%
25.11.20

buy
Borgwarner Inc.

Start price
Target price
Perf. (%)
€33.00
10.11.20
-
10.11.21
10.91%
11.09.21

Below average Marketposition
Business model of the past or high risk
buy
Data I/O Corp.

Start price
Target price
Perf. (%)
€2.86
10.11.20
€4.00
10.11.21
5.59%
16.11.20

Could be worthwhile Investment >10% per year
buy
Innodata Inc.

Start price
Target price
Perf. (%)
€2.34
10.11.20
€4.00
10.11.21
41.03%
16.11.20

Could be worthwhile Investment >10% per year
buy
Marin Software

Start price
Target price
Perf. (%)
€1.66
10.11.20
€3.00
10.11.21
-9.04%
16.11.20

Could be worthwhile Investment >10% per year
buy
Inpixon

Start price
Target price
Perf. (%)
€64.88
10.11.20
€150.00
10.11.21
-1.73%
16.11.20

Could be worthwhile Investment >10% per year
buy
Mandiant Inc.

Start price
Target price
Perf. (%)
€12.90
10.11.20
-
10.11.21
44.21%
19.01.21

Future proof or reliable business model
Innovative
Growths slower than the competition
Beyond Meat Inc

Start price
Target price
Perf. (%)
€100.00
10.11.20
-
04.11.21
15.34%
16.12.20

Revenue growth >5% per year expected
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€50.00
09.11.20
€55.00
2.66%
10.11.20

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€33.30
09.11.20
€37.95
-11.94%
17.12.20

Capable Management
Good culture
Innovative
Differentiated customer and product portfolio
buy
Walmart Inc.

Start price
Target price
Perf. (%)
€124.80
09.11.20
-
09.11.21
2.13%
25.11.20

buy
Oncternal Therapeutics Inc.

Start price
Target price
Perf. (%)
€5.15
08.11.20
€5.00
08.11.21
-29.28%
09.11.21

Could be worthwhile Investment >10% per year
buy
Qorvo Inc.

Start price
Target price
Perf. (%)
€126.00
07.11.20
-
07.11.21
18.25%
24.03.21

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Some uniques
Growths slower than the competition